Neurotech s.a. Announces European CE Mark Approval for the ADNS-300 System to Treat Refractory Epilepsy

Neurotech s.a. Announces European CE Mark Approval for the ADNS-300 System to Treat Refractory Epilepsy PR Newswire LOUVAIN LA NEUVE, Belgium, June 7, 2012 LOUVAIN LA NEUVE, Belgium, June 7, 2012 /PRNewswire/ -- Treatment of Refractory Epilepsy by Vagus Nerve Stimulation to be available in Europe Neurotech s.a. (http://www.neurotech-int.eu), a Belgium based developer and manufacturer of neurostimulation devices, announces that it has obtained the European CE Mark for its ADNS-300 system dedicated to the treatment of refractory epilepsy. The surgically implanted ADNS-300 system delivers mild electrical pulses to the vagus nerve in the neck. Operating as a pacemaker, it produces stimulation towards the brain. "Advens therapy" uses the ADNS-300 stimulator as a therapeutic option for those patients who are refractory to anti- epileptic drugs and are not eligible for epilepsy (brain) surgery. The ADNS-300 is the world's first rechargeable neurostimulator for vagus nerve stimulation. The device includes an innovative electrode and a promising "sensing" feature that may prove to be a significant technological breakthrough in the control of response to the therapy. Patients use a remote controller and charger to turn the system on/off and to recharge the neurostimulator. "Rechargeable systems may prove to be more cost-effective, especially if surgical operations to replace batteries are avoided over time.